Colin P. N. Dinney, MD

Colin P. N. Dinney, MD

University of Texas MD Anderson Cancer Center

Houston, Texas

Colin P. N. Dinney, MD, is the Chairman of the Department of Urology, in the Division of Surgery, and the W.A. "Tex" & D. Moncrief, Jr. Distinguished Chair in Urology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Dinney is also the Co-Chair of the Genitourinary Steering Committee for the Bladder Task Force, also in Houston, Texas. Dr. Dinney has expertise in treating the surgical removal of the bladder. 

Dr. Dinney earned his BS in Microbiology and his MD from the University of Winnipeg in Winnipeg, Canada. He completed his Medicine internship, research fellowship in Surgery, and a research residency in Urology, all at Dalhousie University in Halifax, Canada. Dr. Dinney then completed a research fellowship in Urology at the University of Texas MD Anderson Cancer Center in Houston, Texas. 

Dr. Dinney’s clinical research has focused on understanding the biology of metastatic bladder cancer and developing novel therapeutic strategies for both early and advanced disease. The current focus of his laboratory investigation is the development of immuno-gene therapy for NMIBC, and he directed the clinical development of Nadofaragene firadenovec for BCG-unresponsive NMIBC. Dr. Dinney has over 390 publications covering a wide variety of topics in urologic oncology, with emphasis on bladder cancer.

Talks by Colin P. N. Dinney, MD

Therapy for High Risk NMIBC

Therapy for High Risk NMIBC

| Aug 2024

Colin P.N. Dinney, MD, defines the criteria that categorize patients as high-risk, such as tumor grade, size, and recurrence history. He underscores the importance of early and accurate diagnosis using advanced imaging techniques and molecular markers, which play a crucial role in guiding treatment decisions.

He focuses on Bacillus Calmette-Guérin (BCG) therapy, the gold standard for high-risk NMIBC. Dr. Dinney reviews BCG’s mechanisms of action, administration protocols, and factors influencing its efficacy. He also addresses the challenges posed by BCG shortages and the emergence of BCG-unresponsive disease, highlighting the need for alternative therapeutic strategies.

Further, Dr. Dinney discusses the potential of immune checkpoint inhibitors, targeted therapies, and gene therapy in the context of high-risk NMIBC. He presents data from recent clinical trials that demonstrate the promising results of these innovative approaches in achieving durable responses and reducing recurrence rates.

Read More